Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution

Background: There have not been any head-to-head prospective studies to compare the effects of different chemotherapy regimens as first-line treatments for unresectable pancreatic cancer (UPC). We aimed to compare the effectiveness of nab-paclitaxel plus gemcitabine, mFOLFIRINOX and gemcitabine plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Quan, Qi, Wang, Yixing, Wang, Fenghua, Zhang, Dongsheng, Chen, Xiuxing, He, Wenzhuo, Zhang, Bei, Guo, Guifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816170/
https://www.ncbi.nlm.nih.gov/pubmed/33704188
http://dx.doi.org/10.3390/curroncol28010023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816170/
https://www.ncbi.nlm.nih.gov/pubmed/33704188
http://dx.doi.org/10.3390/curroncol28010023

Ejemplares similares